WADA imposes analytical testing restriction on Polish Anti-Doping Laboratory

Today, the World Anti-Doping Agency (WADA) announced that effective 10 March 2026, and for a period of up to six months, WADA has imposed an Analytical Testing Restriction (ATR) on the Polish Anti-Doping Laboratory (Laboratory), limited to the application of the Confirmation Procedure for the substances related to modafinil (e.g., modafinil acid, modafinil and adrafinil). 

On 4 March 2026, WADA received a recommendation from its Laboratory Expert Advisory Group (Lab EAG) to impose this ATR for non-compliances with the International Standard for Laboratories (ISL). Following the recommendation, on 10 March 2026, the Chair of WADA’s Executive Committee rendered a decision imposing the ATR. 

Pursuant to Article 4.6.4.7 of the ISL, the Laboratory may appeal this decision to the Court of Arbitration for Sport within 21 days of receipt of the decision.  

During the ATR, the Laboratory can continue carrying out its regular anti-doping activities, as per the ISL. However, all routine samples that require confirmation analysis of substances related to modafinil shall be securely transported to another WADA-accredited laboratory. 

According to the ISL, WADA is responsible for accrediting and re-accrediting anti-doping laboratories, thereby ensuring that they maintain the highest quality standards. This monitoring process is conducted in conjunction with International Organization for Standardization (ISO) assessment by independent national accreditation bodies that are full members of the International Laboratory Accreditation Cooperation (ILAC) and signatories to the ILAC Mutual Recognition Arrangement (ILAC MRA).